Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Centessa Pharmaceuticals plc before investing.

In this article, we go over a few key elements for understanding Centessa Pharmaceuticals plc’s stock price such as:

• Centessa Pharmaceuticals plc’s current stock price and volume
• Why Centessa Pharmaceuticals plc’s stock price changed recently
• Upgrades and downgrades for CNTA from analysts
• CNTA’s stock price momentum as measured by its relative strength

About Centessa Pharmaceuticals plc (CNTA)

Before we jump into Centessa Pharmaceuticals plc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.

Want to learn more about Centessa Pharmaceuticals plc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Centessa Pharmaceuticals plc.

Centessa Pharmaceuticals plc’s Stock Price as of Market Close

As of June 05, 2026, 4:00 PM, CST, Centessa Pharmaceuticals plc’s stock price was $39.620.

Centessa Pharmaceuticals plc is down 0.45% from its previous closing price of $39.800.

During the last market session, Centessa Pharmaceuticals plc’s stock traded between $39.615 and $39.810. Currently, there are approximately 153.55 million shares outstanding for Centessa Pharmaceuticals plc.

Centessa Pharmaceuticals plc’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Centessa Pharmaceuticals plc Stock Price History

Centessa Pharmaceuticals plc’s (CNTA) price is currently down 0.35% so far this month.

During the month of June, Centessa Pharmaceuticals plc’s stock price has reached a high of $39.980 and a low of $39.615.

Over the last year, Centessa Pharmaceuticals plc has hit prices as high as $40.260 and as low as $11.550. Year to date, Centessa Pharmaceuticals plc’s stock is up 58.42%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Centessa Pharmaceuticals plc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of June 05, 2026, there was 1 analyst who downgraded Centessa Pharmaceuticals plc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Centessa Pharmaceuticals plc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Centessa Pharmaceuticals plc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Centessa Pharmaceuticals plc (CNTA) by visiting AAII Stock Evaluator.

Relative Price Strength of Centessa Pharmaceuticals plc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of June 05, 2026, Centessa Pharmaceuticals plc has a weighted four-quarter relative price strength of 33.53%, which translates to a Momentum Score of 95 and is considered to be Very Strong.

Want to learn more about how Centessa Pharmaceuticals plc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Centessa Pharmaceuticals plc Stock Price: Bottom Line

As of June 5, 2026, Centessa Pharmaceuticals plc’s stock price is $39.620, which is down 0.45% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Centessa Pharmaceuticals plc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.